202 related articles for article (PubMed ID: 10602338)
1. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution.
Pickavance LC; Tadayyon M; Widdowson PS; Buckingham RE; Wilding JP
Br J Pharmacol; 1999 Dec; 128(7):1570-6. PubMed ID: 10602338
[TBL] [Abstract][Full Text] [Related]
2. Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.
Pickavance LC; Buckingham RE; Wilding JP
Diabetes Obes Metab; 2001 Jun; 3(3):171-80. PubMed ID: 11412281
[TBL] [Abstract][Full Text] [Related]
3. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
Moore GB; Pickavance LC; Briscoe CP; Clapham JC; Buckingham RE; Wilding JP
Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
[TBL] [Abstract][Full Text] [Related]
4. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Finegood DT; McArthur MD; Kojwang D; Thomas MJ; Topp BG; Leonard T; Buckingham RE
Diabetes; 2001 May; 50(5):1021-9. PubMed ID: 11334404
[TBL] [Abstract][Full Text] [Related]
5. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
[TBL] [Abstract][Full Text] [Related]
6. Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Liu YL; Sennitt MV; Hislop DC; Crombie DL; Heyman RA; Cawthorne MA
Int J Obes Relat Metab Disord; 2000 Aug; 24(8):997-1004. PubMed ID: 10951538
[TBL] [Abstract][Full Text] [Related]
7. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y.
Wang Q; Dryden S; Frankish HM; Bing C; Pickavance L; Hopkins D; Buckingham R; Williams G
Br J Pharmacol; 1997 Dec; 122(7):1405-10. PubMed ID: 9421288
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Cai XJ; Lister CA; Buckingham RE; Pickavance L; Wilding J; Arch JR; Wilson S; Williams G
Brain Res Mol Brain Res; 2000 Apr; 77(1):131-7. PubMed ID: 10814839
[TBL] [Abstract][Full Text] [Related]
9. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats.
Naderali EK; Pickavance LC; Wilding JP; Doyle PJ; Williams G
Eur J Pharmacol; 2001 Mar; 416(1-2):133-9. PubMed ID: 11282122
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway.
Yang C; Chang TJ; Chang JC; Liu MW; Tai TY; Hsu WH; Chuang LM
Diabetes; 2001 Nov; 50(11):2598-602. PubMed ID: 11679440
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
13. Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice.
Sundaresan A; Radhiga T; Pugalendi KV
J Physiol Biochem; 2016 Jun; 72(2):345-52. PubMed ID: 27090933
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
Livingstone DE; Kenyon CJ; Walker BR
J Endocrinol; 2000 Dec; 167(3):533-9. PubMed ID: 11115781
[TBL] [Abstract][Full Text] [Related]
15. Reduced anorexic effects of insulin in obesity-prone rats fed a moderate-fat diet.
Clegg DJ; Benoit SC; Reed JA; Woods SC; Dunn-Meynell A; Levin BE
Am J Physiol Regul Integr Comp Physiol; 2005 Apr; 288(4):R981-6. PubMed ID: 15604298
[TBL] [Abstract][Full Text] [Related]
16. Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats.
Gao W; Jusko WJ
J Pharmacol Exp Ther; 2012 Jun; 341(3):617-25. PubMed ID: 22378938
[TBL] [Abstract][Full Text] [Related]
17. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
[TBL] [Abstract][Full Text] [Related]
18. Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids.
Berthiaume M; Sell H; Lalonde J; Gélinas Y; Tchernof A; Richard D; Deshaies Y
Am J Physiol Regul Integr Comp Physiol; 2004 Nov; 287(5):R1116-23. PubMed ID: 15256367
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
[TBL] [Abstract][Full Text] [Related]
20. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
Carey DG; Cowin GJ; Galloway GJ; Jones NP; Richards JC; Biswas N; Doddrell DM
Obes Res; 2002 Oct; 10(10):1008-15. PubMed ID: 12376581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
